Posts tagged acute myeloid leukemia
Roth ups GlycoMimetics PT to $35

Roth Capital Partners raised its price target for GlycoMimetics (NASDAQ:GLYC) to $35 from $25 after the company agreed with the Dutch hematological oncology foundation, HOVON, to move towards a 140-patient study of GMI-1271 in combination with decitabine in newly-diagnosed patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) unfit for chemotherapy induction.

Read More
BioSight closes investment from Arkin, Primera

Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital.

Proceeds will be used for a multi-center, Phase 2b clinical trial with the company’s lead product, Astarabine, for the treatment of acute myeloid leukemia (AML).

Read More
Stifel starts Celator Pharma at buy

Stifel has initiated coverage of Celator Pharmaceuticals (NASDAQ:CPXX) with a “buy” rating and a 12-month target price of $23. The stock closed at $15.52 on Thursday.

Analyst Stephen Willey writes that recently-announced Phase 3 data, demonstrating Vyxeos confers a statistically-significant improvement in overall survival versus traditional cytarabine/daunorubicin chemotherapy (“7+3”) in patients aged 60-to-75 with high-risk/secondary acute myeloid leukemia (AML), represents the first meaningful therapeutic advancement in AML since conventional “7+3” chemotherapy became the backbone of intensive induction therapy more than 40 years ago.

Read More
BioSight completes Phase 1/2a leukemia trial

Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months.

The Phase 1/2a trial is an open-label study to evaluate the safety and efficacy of Astarabine as single agent in adults with acute myeloid leukemia (AML) and relapsed/refractory acute lymphoblastic leukemia (ALL).

Read More
Rodman starts Bio-Path at buy

Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday.

“In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid leukemia (AML),” writes analyst Raghuram Selvaraju.

Read More